EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Comprehensive Exploration of Unexplained Dyspnoea in Subjects with Normal Ejection Fraction and Low Natriuretic Peptides

Emmanuelle Berthelot iD, Tarek Laouar, Antoine Beurnier, Nataliya Hrynchynshyn, Jean Christophe Eicher, Jean-Michel Tartière, Patrick Jourdain, Olivier Lairez, Barnabas Gellen

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Emmanuelle Berthelot und 8 weiteren Autor:innen. Beteiligte Einrichtung: AP-HP, Department of Cardiology, Bicêtre Hospital, Le Kremlin-Bicêtre, France. Hauptthemen laut MEDLINE: Dyspnea, Stroke Volume, Natriuretic Peptide, Brain, Peptide Fragments. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bourse 2017 of the French Society of Cardiology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Unexplained exertional dyspnoea without significant elevation of natriuretic peptides is common. One of the causes might be early heart failure with preserved ejection fraction (HFpEF).

Aims

This study aimed to characterize patients with exertional dyspnoea and normal/near-to-normal N-terminal pro-brain natriuretic peptide (NT-proBNP) levels with regard to early stages of HFpEF and non-cardiac causes. Method and Results Sixty-six patients (age 62 ± 7 years old, 85% women) with dyspnoea assessed using the Multidimensional Dyspnea Profile (MDP) questionnaire and NT-proBNP level of <125 pg/mL for patients <75 years old or <300 pg/mL for patients >75 years old were recruited. Patients with known significant heart disease, lung disease (abnormal respiratory function tests) or renal insufficiency stage ≥ 4 were excluded. In 11 patients (16.7%), HFpEF was confirmed according to the European Society of Cardiology Heart Failure Association (ESC HFA) criteria, 31 patients (47%) presented isolated deconditioning and 5 patients (7.6%) had idiopathic hyperventilation. In the remaining 19 patients (28.8%) with normal echocardiography and cardiopulmonary exercise testing (CPX), no objective cause of dyspnoea could be found. Compared with patients without HFpEF, those with HFpEF were older, more often hypertensive and diabetic, with higher NT-proBNP levels. They had higher E/e′ ratios during exercise echocardiography and lower volume of oxygen uptake (VO2) peaks and steeper minute ventilation (VE)/volume of carbon dioxide produced (VCO2) slopes during CPX. Psychological impact measured on the Short Form-36 (SF-36) questionnaire was less important in HFpEF patients than in other patients.

Conclusions

The most common causes of unexplained exertional dyspnoea in patients without significant elevation of natriuretic peptides are peripheral deconditioning, HFpEF and hyperventilation. Studying patients during exercise allows for getting more data about pathophysiology and improving patient phenotyping and management. Early unmasking of HFpEF using exercise echocardiography and/or CPX and initiation of treatment could prevent hospitalizations for acute heart failure. Although using exercise testing, many patients could not be classified according to their diagnosis, and this reinforces the need to better define exercise diagnostic criteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DyspneaStroke VolumeNatriuretic Peptide, BrainPeptide FragmentsHeart FailureExercise ToleranceVentricular Function, LeftHumansFemaleMaleMiddle AgedAgedExercise TestBiomarkersEchocardiography

Stichwörter der Autor:innen

HFpEFNT‐proBNPdiagnosisdyspnoeaoxygen consumption

Substanzen

Natriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Biomarkers

Autor:innen und Institutionen

  • AP-HP, Department of Cardiology, Bicêtre Hospital, Le Kremlin-Bicêtre, France.
  • AP-HP, Departement of Physiology - Functional Explorations, DMU 5 Thorinno, bi-site Bicêtre (Le Kremlin Bicêtre) and Ambroise Paré (Boulogne-Billancourt) Hospitals, Le Kremlin-Bicêtre, France.
  • Université Paris-Saclay, INSERM, UMR_S 999, Hypertension Pulmonaire: Physiopathologie and Innovation Thérapeutique (HPPIT), AP-HP, Hôpital Bicêtre, Hôpital Marie Lannelongue (Groupe Hospitalier Paris Saint Joseph), ERN-…
  • CHU de Dijon, Hôpital François Mitterrand, Dijon, France.
  • Sainte Musse Hospital, Department of Cardiology and Direction de la Recherche Clinique et de l'Innovation, CHITS, Toulon, Var, France.
  • Toulouse 3 - Paul Sabatier University, University Hospital, Department of cardiology, Toulouse Cedex 9, France.

ORCID-Profile: Emmanuelle Berthelot

Förderung

  • Bourse 2017 of the French Society of Cardiology

Zitieren

APA

Berthelot, E., Laouar, T., Beurnier, A., Hrynchynshyn, N., Eicher, J. C., Tartière, J. M., Jourdain, P., Lairez, O., & Gellen, B. (2025). Comprehensive Exploration of Unexplained Dyspnoea in Subjects with Normal Ejection Fraction and Low Natriuretic Peptides. ESC Heart Failure. https://doi.org/10.1002/ehf2.15059

Vancouver

Berthelot E, Laouar T, Beurnier A, Hrynchynshyn N, Eicher JC, Tartière JM, et al. Comprehensive Exploration of Unexplained Dyspnoea in Subjects with Normal Ejection Fraction and Low Natriuretic Peptides. ESC Heart Failure. 2025. doi:10.1002/ehf2.15059

BibTeX
@article{Berthelot2025,
  author = {Berthelot, Emmanuelle and Laouar, Tarek and Beurnier, Antoine and Hrynchynshyn, Nataliya and Eicher, Jean Christophe and Tartière, Jean-Michel and Jourdain, Patrick and Lairez, Olivier and Gellen, Barnabas},
  title = {Comprehensive Exploration of Unexplained Dyspnoea in Subjects with Normal Ejection Fraction and Low Natriuretic Peptides},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15059}
}
Kostenlos starten →